Surgical robotics maker Shenzhen Edge Medical Co. Ltd. reported its initial public offering on the Hong Kong Stock Exchange to raise HKD$1.19 billion (US$154 million) to advance its pipeline of surgical robotic systems and expand its geographic footprint to markets outside China. To be listed on the main board of the Hong Kong Stock Exchange (HKEX: 02675), the global offering consists of 27.72 million H shares priced at HKD$43.24 per share. The funds will support R&D investments, added manufacturing capacity, and expansion of its international footprint. The company is expected to list on Jan. 8, 2026, according to the prospectus. Morgan Stanley and GF Capital (Hong Kong) are the joint sponsors.

Med-tech IPOs shoot for the stars in 2025

IPOs top the list of the big stories in 2025 in med tech. Thirty med-tech companies went public, raising nearly $12 billion, two orders of magnitude more than in 2023 and almost 20 times more than raised in 2024. IPOs in 2025 demonstrated broad support globally for med-tech companies, with two of the three largest hailing from Europe – Sweden's Asker Healthcare Group BV and Germany’s Ottobock SE KGaA. Notably, Ottobock’s October IPO represented the largest IPO in Germany in 18 months and The Beauty Tech Group’s listing that same month raised the total value of IPOs on the London Stock Exchange in 2025 by 68%. Diagnopstyka Sp. Z o.o.’s IPO brought the Krakow exchange to life in February with its $415 million IPO.

CMR, Medtronic secure FDA nod for robotic surgical systems

The U.S. FDA recently cleared Medtronic plc’s Hugo robotic-assisted surgery (RAS) system and CMR Surgical Ltd.’s Versius Plus system, adding new options to the U.S. market to meet rising demand for robotic procedures. While Intuitive Surgical Inc. currently dominates the soft tissue surgical robotics space, these new entrants will provide hospitals and health care systems with greater choices when it comes to purchasing systems and expanding systems.

FDA declines to clarify on-site access restrictions in BiMo final

The U.S. FDA’s final guidance for clinical trial inspections conducted under the bioresearch monitoring (BiMo) program seems to deviate little if at all from the 2024 draft, but that is precisely the rub for some stakeholders. The Advanced Medical Technology Association pressed the agency to ensure that the final guidance considers the hazards of electronic access during remote BiMo audits, but the final guidance makes no such concessions.

Advanced Biomed sells Hong Kong subsidiary for $23k

Advanced Biomed Inc. reported Dec. 30 the sale of its wholly owned Hong Kong subsidiary, Advanced Biomed (HK) Ltd., and related intellectual property (IP) to buyer Wei Ha Hui for $23,000. The deal, signed Dec. 23, 2025, transferred 100% of issued and outstanding shares of the Hong Kong entity and its IP. The transaction also included IP owned by Shanghai-based Sglcell Biotech Co. Ltd., a wholly owned subsidiary of Advanced Biomed (HK) Ltd. “In light of evolving regulatory requirements on clinical trials and data in China, and to accelerate development and commercialization of our products and solutions, we decided to divest the assets of Hong Kong and Shanghai subsidiaries,” Advanced Biomed CEO Yi Lu said. “All clinical trials will now be centralized and conducted through our Taiwan subsidiary, which we believe will be part of our strategic realignment.”

Also in the news

Advanced Biomed, Biobeat, HAI Solutions, Koru Medical Systems, Positron, Profound Medical, Sensiva Health

Notice of email fulfillment change

Effective Jan. 5, 2026, BioWorld is switching email fulfillment services. While we have made every effort to ensure that all current user subscription details — as well as information on users who have unsubscribed — have been migrated accurately to the new system, there may be a few instances where certain information may not have carried over as expected. If you have any concerns that you received a newsletter in error or if a colleague has not received an expected newsletter, do not hesitate to reach out to our customer care team. You can submit a query. Or call us:

  • Americas: 855-258-3279
  • Europe, Middle East, and Africa: +44 8081 963232

Going forward, if you would like to be unsubscribed, click on the ‘Unsubscribe’ link at the bottom of the emailed newsletter.